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Abstract. Severe acute respiratory syndrome (SARS) 
coronavirus-2 (SARS-coV-2) enters into human host cells 
via mechanisms facilitated mostly by angiotensin-converting 
enzyme 2 (AcE2) and transmembrane protease serine 2 
(TMPRSS2). New loss of smell (anosmia/hyposmia) is now 
recognized as a cOVId-19 related symptom, which may 
be caused by SARS-coV-2 infection and damage of the 
olfactory receptor (OR) cells in the nasal neuro-epithelium 
and/or central involvement of the olfactory bulb. ORs are also 
expressed peripherally (e.g., in tissues of the gastrointestinal 
and respiratory systems) and it is possible that their local 
functions could also be impaired by SARS-coV-2 infection 
of these tissues. Using Gene Expression Profiling Interactive 
Analysis, The cancer Genome Atlas, Genotype-Tissue 
Expression, cBioPortal and Shiny Methylation Analysis 
Resource Tool, we highlight the expression of peripheral 
ORs in both healthy and malignant tissues, and describe their 
co-expression with key mediators of SARS-coV-2 infection, 
such as AcE2 and TMPRSS2, as well as cathepsin L (cTSL; 
another cellular protease mediating SARS-coV-2 infection 
of host cells). A wide expression profile of peripheral ORs 
was noted, particularly in tissues such as the prostate, testis, 
thyroid, brain, liver, kidney and bladder, as well as tissues 
with known involvement in cardio-metabolic disease (e.g., the 
adipose tissue, pancreas and heart). Among these, OR51E2, 
in particular, was significantly upregulated in prostate 
adenocarcinoma (PRAd) and co-expressed primarily with 
TMPRSS2. Functional networks of this OR were further 
analysed using the GeneMANIA interactive tool, showing 
that OR51E2 interacts with a plethora of genes related to 
the prostate. Further in vitro and clinical studies are clearly 
required to elucidate the role of ORs, both at the olfactory level 
and the periphery, in the context of cOVId-19.
Introduction
The ongoing cOVId-19 pandemic caused by the severe acute 
respiratory syndrome (SARS) coronavirus-2 (SARS-coV-2) 
infection has affected over 6.5 million people thus far, resulting 
in the death of over four hundred thousand individuals world-
wide (1). Recently, new loss of the sense of smell, either total 
(anosmia) or partial (hyposmia), has been recognised as a 
symptom of cOVId-19 by the World Health Organisation 
(WHO) and the US centres for disease control and Prevention 
(cdc) (www.cdc.gov/coronavirus/2019-ncov/symp-
toms-testing/symptoms.html).
Accordingly, additional research focus has now been 
placed on exploring anosmia and the involvement of olfac-
tory receptors (ORs) in cOVId-19 (2). Although poorly 
defined, more than 400 functional ORs are expressed in 
the human body, with corresponding ligands which remain 
mostly unclassified (3). Thought to be located primarily in 
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the olfactory epithelium of the nasal cavity, these G-Protein 
coupled Receptors (GPcRs) are also known to be expressed 
in peripheral tissues (4). As such, in humans, ORs are involved 
in additional processes/pathways other than those for smell 
perception, which have been identified to mediate physiological 
functions in the cardiovascular, gastrointestinal and respira-
tory system (5,6). For example, ORs appear to be involved in 
widespread chemosensory systems, with OR51E2 expressed 
in the airway smooth muscle acting on processes which lead 
to increased airway smooth muscle mass that is a hallmark 
of asthma (4). Of note, the severity of cOVId-19 shows a 
positive association with certain comorbidities which affect 
these tissues/systems, including asthma, obesity, diabetes and 
cancer (7).
Fusion of the SARS-coV-2 spike proteins with the host 
transmembrane receptor angiotensin-converting enzyme 2 
(AcE2) is shown to instigate spike protein cleavage through 
interaction with cellular proteases, such as transmembrane 
protease serine 2 (TMPRSS2), consequently allowing viral 
entry into the host cell (8,9). Additional intracellular prote-
ases, such as cathepsin L (cTSL), might also mediate host cell 
infection by SARS-coV-2 (8,9). Upon entry, the virus is then 
able to cause cellular damage and instigate a response which 
may result in a spectrum of clinical sequelae, ranging from 
anosmia to pneumonia, respiratory failure, cardiovascular 
distress and death (10).
Given the negligible expression of AcE2 and TMPRSS2 
in olfactory neuronal cells and substantial expression in the 
olfactory epithelium, it has been postulated that sustentacular 
cells (supporting cells) are also involved in local viral entry 
and anosmia (11). Additional evidence including the expres-
sion of AcE2 and TMPRSS2 by the olfactory mucosa 
supports the notion that SARS-coV-2 is capable of infecting 
non-neuronal cell types and, thus, subsequently disrupt odour 
perception (12).
The present study aimed to identify, both in normal and 
cancer tissues, the co-expression profile of a number of ORs 
which are known to be expressed in peripheral tissues in 
relationship to key mediators of the SARS-coV-2 infection, 
namely AcE2, TMPRSS2 and cTSL. As such, concentrating 
on non-neuronal (peripheral) expression of ORs, here we 
provide a comprehensive analysis of the expression profile of 
ORs in peripheral tissues, several of which co-express AcE2, 
TMPRSS2 and cTSL and are correspondingly associated with 
comorbidities predisposing to severe cOVId-19 (Fig. 1).
Data collection methods
Bioinformatic analysis. Expression analysis of AcE2, cTSL, 
TMPRSS2, OR51E2, OR10Q1, OR2A1, OR2W3, OR1J4, 
OR2A7, OR1Q1, OR6A2, OR1J1 and OR4M1 were validated 
through the Genotype-Tissue Expression (GTEx), The cancer 
Genome Atlas (TcGA) and GEPIA (http://gepia.cancer). 
Information regarding TcGA cohort pan-cancer data and 
methylation data acquired through cBioPortal (http://www.
cbioportal.org/) and Shiny Methylation Analysis Resource Tool 
(SMART) (http://www.bioinfo-zs.com/smartapp). Network 
localisation data were acquired through GeneMANIA soft-
ware (http://genemania.org). data sets accessed for pan-cancer 
analysis: Acc, adrenocortical carcinoma; BLcA, bladder 
urothelial carcinoma; BRcA, breast invasive carcinoma; 
cESc, cervical squamous cell carcinoma and endocervical 
adenocarcinoma; cHOL, cholangiocarcinoma; cOAd, colon 
adenocarcinoma; dLBc, lymphoid neoplasm diffuse large 
B cell lymphoma; EScA, oesophageal carcinoma; GBM, 
glioblastoma multiforme; HNSc, head and neck squamous 
cell carcinoma; KIcH, kidney chromophobe; KIRc, kidney 
renal clear cell carcinoma; KIRP, kidney renal papillary cell 
carcinoma; LAML, acute myeloid leukaemia; LGG, brain 
lower grade glioma; LIHc, liver hepatocellular carcinoma; 
LUAd, lung adenocarcinoma; LUSc, lung squamous cell 
carcinoma; MESO, mesothelioma; OV, ovarian serous cyst-
adenocarcinoma; PAAd, pancreatic adenocarcinoma; PcPG, 
pheochromocytoma and paraganglioma; PRAd, prostate 
adenocarcinoma; REAd, rectum adenocarcinoma; SARc, 
sarcoma; SKcM, skin cutaneous melanoma; STAd, stomach 
adenocarcinoma; TGcT, testicular germ cell tumours; THcA, 
thyroid carcinoma; THyM, thymoma; UcEc, uterine corpus 
endometrial carcinoma; UcS, uterine carcinosarcoma and 
UVM, uveal melanoma.
Results
Using GTEx Multi Gene Query expression, data was obtained 
for the assessment of ten ORs in normal tissues (Fig. 2). These 
data show that: OR51E2 is primarily expressed in the prostate, 
arteries and colon; OR10Q1 is expressed in adipose tissue, 
breast, salivary gland, pancreas and testis; OR2A1 exhibited 
a much wider distribution in adipose tissue, arteries, breast, 
fibroblasts, cervix, lung, tibial nerve, ovary, skin, thyroid, uterus 
and vagina; OR2W3 is primarily expressed in tibial nerve, 
brain, thyroid and whole blood; OR1J4 is primarily expressed 
in the bladder, fibroblasts, cervix, lung, salivary gland, and 
testis; OR2A7 is highly expressed in the bladder, breast, colon, 
oesophagus, skin, small intestine, thyroid, lung and vagina; 
OR1Q1 is primarily expressed in the bladder and fibroblasts; 
OR6A2 exhibited high expression in the bladder, testis, thyroid, 
uterus and vagina; OR1J1 is primarily expressed in the bladder, 
fibroblasts, and testis. Information regarding the expression of 
OR4M1 in healthy tissues is limited (expression in testis only) 
with mapping and classification being an ongoing process.
Fig. 3 presents the GTEx gene expression data regarding 
the co-expression of ORs with AcE2, TMPRSS2 and cTSL in 
multiple normal tissues, including the lungs, oesophagus, sali-
vary gland, colon, testis, thyroid and kidney, as well as tissues 
with established involvement in cardio-metabolic syndrome 
(e.g., the heart, pancreas and adipose tissue). These data 
corroborate recent findings showing relatively high expression 
of ACE2 and CTSL in the majority of tissues assessed, with 
varying levels of TMPRSS2 recorded (13,14).
Given that cancer is concidered as a comorbididity which 
predisposes to severe cOVId-19, we also investigated the 
pan-cancer expression of ORs, including data regarding meth-
ylation and mutational profiles. Using the TCGA datasets for 
all cancers, only four ORs appeared to be significantly differ-
entially regulated (Fig. 4). OR2A1 was down-regulated in OV 
and THCA; OR2W3 was down-regulated in THYM; OR2A7 
was down-regulated in SKcM and THcA; whereas OR51E2 
was down-regulated in cOAd and REAd but up-regulated in 
PRAd.
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Subsequently, using the SMART tool, the promoter 
methylation status of these ORs in comparison to AcE2, 
TMPRSS2 and cTSL was also investigated (Fig. 5). data sets 
without comparable normal tissue have been removed (all OR 
methylation data can be viewed in Fig. S1). Lower promoter 
methylation often indicates higher protein gene expression due 
to reduced inhibition of the promoter region. However, despite 
the extensive data regarding decreased methylation status 
within an array of data sets, when compared with GEPIA 
expression data, changes in methylation status of nine ORs 
did not significantly correlate with changes in gene expression. 
Of the differentially methylated genes, only OR51E2 exhibits 
both lower tumour methylation and significant increase in 
gene expression in PRAd (Fig. 4).
Finally, the data from cBioPortal revealed that the highest 
level of alterations in the data set for these ORs relates to gene 
amplification or mutation across the cancer panel (Fig. 6). 
Supplementary Fig. S2 presents further breakdown of this 
mutational profile. Of note, melanoma appears to have a high 
frequency of OR alterations compared to the other cancer 
types, while the only OR to present with an alteration in the 
form of a fusion is OR51E2 in PRAd.
Discussion
In this in silico study, we present novel evidence regarding the 
peripheral tissue distribution of ORs and their co-expression 
pattern in relationship to key mediators of SARS-coV-2 infec-
tion. The potential involvement of ORs in the loss of smell as 
one of the cOVId-19 presenting symptoms has been hypoth-
esized since the first clinical cases of COVID-19 patients with 
anosmia (15). Based on our present findings, it is plausible 
that SARS-coV-2 infection may exert damage and impair 
the function of ORs, not only in the nasal epithelium, but also 
peripherally with wider implications.
Indeed, given the known expression and involvement 
of the airway smooth muscle ORs in bronchodilation and 
airway relaxation (5); such peripheral expression of ORs may 
have additional implications relating to cOVId-19. As such, 
damage and potential interference with signalling pathways 
associated with OR functions, as noted for nasal epithelial 
ORs, may contribute to underlying mechanisms predisposing 
to adverse cOVId-19 related clinical outcomes in patients 
with certain comorbidities (e.g., asthma or cancer) (16). In 
addition, our findings suggest potential links which should 
be explored in the context of male preponderance for severe 
cOVId-19, given that a number of ORs were overexpressed 
in testes. Indeed, the latter is an organ prone to infections by 
other viruses, including HIV, hepatitis or papilloma among 
other, which can cause viral orchitis or even lead to testicular 
cancer (17). Therefore, the possibility that the testes represents 
an additional target organ for SARS-coV-2 merits further 
investigation.
The notion that SARS-coV-2 infection might induce 
transcriptional changes of ORs is also supported by available 
data regarding effects of SARS-coV infection on gene expres-
sion profiles. For example, a study by Reghunathan et al (18) 
in patients with SARS showed that this viral infection can 
alter the expression of immune response genes. SARS-coV 
transfected monocytes have been shown to exhibit changes 
Figure 1. Following entry of SARS-coV-2 into host cells which is facilitated by AcE2 and TMPRSS2, the function of ORs could be potentially impaired 
(in part or completely) in infected olfactory and peripheral tissues where ORs are also expressed. The present research highlights the expression of peripheral 
ORs in both healthy and malignant tissues and identifies their co-expression with key mediators of SARS-CoV-2 infection, such as ACE2 and TMPRSS2. 
Further research is required to explore whether this co-expression could potentially have additional cOVId-19 related consequences due to damage of infected 
cells expressing ORs and/or impaired OR function in these peripheral tissues, in a similar way to SARS-coV-2 infection causing loss of smell (anosmia) which 
is now recognized as a cOVId-19 related symptom. AcE2, angiotensin-converting enzyme 2; TMPRSS2, transmembrane protease serine 2; ORs, olfactory 
receptors.
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Figure 2. Expression of ORs in normal peripheral tissues using the GTEx database. Wide range of expression was noted for OR51E2, OR2A7, OR10Q1, 
OR1Q1, OR2A1, OR6A2 and OR2W3. OR2W3 shows the highest level of tissue specific expression, whilst OR1J1 and OR1J4 show minimal levels of protein 
expression. ORs, olfactory receptors.
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in immune-related genes, such as interferons, cathepsin and 
cytokine-related signalling genes (19). Of note, murine lung 
epithelial cells infected by another coronavirus (MHV-1) 
have been shown to exhibit certain gene expression changes, 
including downregulation of an OR (OLFR291), and changes 
in other components downstream of GPcR signalling (20).
In the present study, a comprehensive map of differential 
methylation of ORs across a wide repertoire of cancers is 
Figure 3. GTEx Multi Gene Query Map showing the co-expression of of ACE2, TMPRSS2, CTSL and peripheral ORs in normal tissues. Relitively high co-expres-
sion of ORs in relation to AcE2, TMPRSS2 and cTSL is documented in the colon, testis and thyroid. cTSL is vastly expressed throughout the full range of these 
tissues. AcE2, angiotensin-converting enzyme 2; TMPRSS2, transmembrane protease serine 2; cTSL, cathepsin L; ORs, olfactory receptors.
Figure 4. Pan-cancer expression of ORs. (A) Significant decrease in the expression of OR2A1 in OV and THCA tumours (Red) compared to normal (Grey). 
(B) Significant decrease in tumour expression of OR2W3 for THYM. (C) Significant increase in expression of OR51E2 in PRAD and decrease in COAD and READ 
tumour data set. (D) Significant decrease of OR2A7 in both SKCM and THCA. ORs, olfactory receptors; OV, ovarian serous cystadenocarcinoma; THCA, thyroid 
carcinoma; THyM, thymoma; PRAd, prostate adenocarcinoma; cOAd, colon adenocarcinoma; REAd, rectum adenocarcinoma; SKcM, skin cutaneous melanoma.
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Figure 6. Pan-cancer view of OR gene alterations (cBioPortal). OR51E2, expressed a high number of mutations and a fusion in the prostate; OR2A7-OR2A1, 
alterations are primarily amplification; OR10Q1, range of amplifications, most frequent level of mutations recorded in melanoma and non-small cell lung 
cancer; OR4M1, high frequency of mutation in melanoma and notable frequency of deep deletions in stomach adenocarcinoma; OR1J4-OR1J1, range of 
mutations, amplifications and deletions. OR, olfactory receptor.
Figure 5. Pan-cancer methylation analysis of OR genes co-expressed with AcE2, TMPRSS2 and cTSL. cTSL: higher expression across a number of tumour 
sets (blue). ORs: the majority of data sets indicate lower methylation within tumour samples (yellow). High percentage of differentially methylated ORs across 
14 cancers within the panel. No statistically significant difference detected (light blue). Data sets with an absence of control were omitted from this graph. ORs, 
olfactory receptors, AcE2, angiotensin-converting enzyme 2; TMPRSS2, transmembrane protease serine 2; cTSL, cathepsin L.
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provided. changes in dNA methylation can be one of the 
many steps towards malignant transformation (21). It is 
noteworthy that, among the studied ORs, OR51E2 was signif-
icantly overexpressed in PRAd with no apparent difference 
in the expression between caucasian and African American 
groups. Notably, previous studies have implicated this OR 
in prostate cancer (6,22), whilst 19-hydroxyandrostenedione 
(a testosterone metabolite) is endogenously produced upon 
OR51E2 activation (23). Interestingly, it has been suggested 
that androgen sensitivity can be a determinant of the severity 
cOVId-19 manifests (24). Moreover, increased TMPRSS2 
expression has also been recorded for the prostate (14,25). 
The noted high levels of TMPRSS2 and cTSL expression, 
coupled with the presented data regarding OR expression 
(e.g., OR51E2) in malignant and healthy tissues suggest 
additional implications which merit further research; for 
example, regarding increased expression in the prostate and 
predisposition to severe cOVId-19 documented in male 
patients (14,25).
Interestingly, using the GeneMANIA software to gain 
better insight into the network of genes interacting with 
OR51E2, co-expression was noted with a plethora of genes 
related to prostate cancer (Fig. 7). One of the suggested 
interactions of this receptor is with KLK3 (kallikrein 3 or 
prostate specific antigen; PSA). KLK2 and KLK4 are also 
amongst the genes interacting with OR51E2 and are consid-
ered potential biomarkers for screening and monitoring of 
prostate cancer (26). Similarly, OR51E2 interactions were 
also noted with anoctamin 7 (ANO7), a prostate specific 
gene associated with aggressive disease; NKX3.1, a pros-
tatic tumour suppressor gene; as well as prostate cancer 
susceptibility candidate 1 (PRAc1) (27,28). Knockdown of 
PRAc1 in human prostate epithelial stem cells has been 
shown to compromise their sphere formation in vitro (29). 
Furthermore, as a GPcR, OR51E2 interacts with arrestin β2 
(ARRβ2) which has been shown to be involved in β-2 
adrenergic receptor signalling, inducing prostate cancer cell 
progression (30). Finally, OR51E2 also appears to interact 
with serine/threonine kinase 3 (AKT3), a well characterised 
kinase that has been shown to promote prostate cancer cell 
proliferation (31).
In conclusion, the present study offers new data regarding 
the expression of ORs in peripheral tissues and their 
co-expression pattern with key mediators of SARS-coV-2 
cell entry and infection (i.e., AcE2, TMPRSS2, and cTSL). 
Involvement of impaired OR signalling/function due to 
SARS-coV-2 infection leading, not only in anosmia, but 
also in sequelae from other peripheral tissues (e.g., from the 
respiratory system or the prostate) is an intriguing hypoth-
esis which merits further investigation in order to clarify the 
complete spectrum of OR functions that may be impaired in 
cOVId-19. We acknowledge the limitations of our in silico 
approach, thus further in vitro, in vivo and clinical studies 
are clearly required to elucidate the role of ORs, both 
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Figure 7. Network annotation of genes interacting with olfactory receptor OR51E2 (GeneMANIA). Visual representation of prostate specific genes and 
prostate specific biomarkers, such as KLK2 and KLK4, co-expressed (purple), have physical interactions (pink) and co-localised (blue) with OR51E2.
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